{"analyses":[{"ciLowerLimit":"17.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"35.36","estimateComment":"95% CI for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"P-value was assessed using CMH test stratified by the IvRS randomization stratification factors.","paramType":"Difference in Response Rates","paramValue":"26.39","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.70","upperLimit":"29.35","value":"23.1"},{"groupId":"OG001","lowerLimit":"42.68","upperLimit":"56.40","value":"49.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"description":"CRR was defined as the rate of a clinical response of CR or CRi according to IWCLL 2008 criteria. CR requires all of the following: peripheral blood lymphocytes below 4x10\\^9/L, absence of lymphadenopathy by physical examination and CT scan, no hepatomegaly or splenomegaly, absence of disease or constitutional symptoms, blood counts of neutrophils \\>1.5\\*10\\^9/L, platelets \\>100\\*10\\^9/L and hemoglobin \\>110 g/L, bone marrow at least normocellular for age without clonal infiltrate (except for Cri).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles comprised 28 days.","id":"OG000","title":"Obinutuzumab + Chlorambucil"},{"description":"Participants received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised 28 days.","id":"OG001","title":"Obinutuzumab + Venetoclax"}],"paramType":"NUMBER","populationDescription":"ITT population was defined as all randomized participants.","reportingStatus":"POSTED","timeFrame":"At the completion of treatment assessment 3 months after treatment completion (at approximately 15 months)","title":"Percentage of Participants With a Complete Response Rate (CRR) at the Completion of Treatment Assessment as Determined by the Investigator According to IWCLL Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}